Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ZYUS Life Sciences (TSE:ZYUS)
TSXV:ZYUS
RESEARCH TOOLSreports
Holding TSE:ZYUS?
Track your performance easily
See the Price Targets and Ratings of:
ZYUS Analyst Ratings
Currently, no data available
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ZYUS Stock 12 Month Forecast
There Are No Analyst Ratings for TSE:ZYUS In The Last 3 Months.
| Highest Price Target― | Average Price Target― | Lowest Price Target― |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
ZYUS Financial Forecast
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Roth MKM
C$4
Buy
284.62%
Upside
Initiated
03/14/24
Roth/MKM Starts ZYUS Life Sciences Corp (ZYUS:CN) at Buy, 'Unique Cannabinoid Drug Development for Pain Markets'The analyst comments "We are initiating coverage of Zyus Life Sciences with a Buy rating and a C$4.00 price target. Zyus is leveraging its years of cannabinoid formulation expertise to develop cannabinoid drugs for commercialization into the large chronic pain market. Its lead candidate, Trichomylin (Phase 2b), is well positioned to reset valuation on efficacy and significant opioid-sparing data in cancer-related pain market over the next 1-2 years. With two other drugs in the pipeline, we see Zyus as undervalued as a potential disruptor in pharmaceutical cannabinoidbased drugs. Our Buy thesis on ZYUS shares is based on our belief that the company's developmental drug Trichomylin will 1) have positive Phase 2b clinical data (2025), 2) garner Big Pharma interest, 3) ultimately achieve FDA approval, and 4) generate significant commercial revenues in the large chronic pain market."
Stifel Nicolaus
C$1.5
Buy
44.23%
Upside
Initiated
01/26/24
Stifel Canada Resumes ZYUS Life Sciences Corp (ZYUS:CN) at Speculative BuyStifel Canada analyst Justin Keywood resumes coverage on ZYUS Life Sciences Corp (ZYUS:CN) with a Speculative Buy rating and a price target of Cdn$1.50.
Best Analysts Covering ZYUS Life Sciences
Which Analyst Should I Follow If I Want to Buy TSE:ZYUS and Sell After:
1 Month
xxx
Success Rate
1/1 ratings generated profit
Average Return
+9.70%
initiated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +9.70% per trade.
3 Months
xxx
Success Rate
1/1 ratings generated profit
Average Return
+14.10%
initiated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +14.10% per trade.
1 Year
Success Rate
1/1 ratings generated profit
Average Return
+13.00%
initiated a buy rating 10 months ago
Copying Justin Keywood's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +13.00% per trade.
2 Years
xxx
Success Rate
1/1 ratings generated profit
Average Return
+13.00%
initiated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +13.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ZYUS Analyst Recommendation Trends
Rating
Jul 23
Jan 24
Mar 24
Strong Buy
1
2
3
Buy
0
0
0
Hold
0
0
0
Sell
0
0
0
Strong Sell
0
0
0
total
1
2
3
Each month's total comprises the sum of three months' worth of ratings.
ZYUS Stock Forecast FAQ
What is TSE:ZYUS’s average 12-month price target, according to analysts?
Currently, no data Available
What is TSE:ZYUS’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for TSE:ZYUS, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TSE:ZYUS a Buy, Sell or Hold?
Currently, no data Available
What is ZYUS Life Sciences’s price target?
Currently, no data Available
What do analysts say about ZYUS Life Sciences?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of TSE:ZYUS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.